| Literature DB >> 33396604 |
Kenji Tsukigawa1,2, Shuhei Imoto1,2, Keishi Yamasaki1,2, Koji Nishi1, Toshihiko Tsutsumi3, Shoko Yokoyama3, Yu Ishima4, Masaki Otagiri1,2.
Abstract
In a previous study, we reported on the development of a synthetic polymer conjugate of pirarubicin (THP) that was formed via an acid-labile hydrazone bond between the polymer and the THP. However, the synthetic polymer itself was non-biodegradable, which could lead to unexpected adverse effects. Human serum albumin (HSA), which has a high biocompatibility and good biodegradability, is also a potent carrier for delivering antitumor drugs. The objective of this study was to develop pH-sensitive HSA conjugates of THP (HSA-THP), and investigate the release of THP and the cytotoxicity under acidic conditions in vitro for further clinical development. HSA-THP was synthesized by conjugating maleimide hydrazone derivatives of THP with poly-thiolated HSA using 2-iminothiolane, via a thiol-maleimide coupling reaction. We synthesized two types of HSA-THP that contained different amounts of THP (HSA-THP2 and HSA-THP4). Free THP was released from both of the HSA conjugates more rapidly at an acidic pH, and the rates of release for HSA-THP2 and HSA-THP4 were similar. Moreover, both HSA-THPs exhibited a higher cytotoxicity at acidic pH than at neutral pH, which is consistent with the effective liberation of free THP under acidic conditions. These findings suggest that these types of HSA-THPs are promising candidates for further development.Entities:
Keywords: HSA-drug conjugates; cytotoxicity; drug release; human serum albumin (HSA); pH-sensitive; pirarubicin (THP)
Year: 2020 PMID: 33396604 PMCID: PMC7823624 DOI: 10.3390/ph14010022
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247